Major Drug Makers; Johnson & Johnson (JNJ) and Eli Lilly (LLY) Database Collaboration – JNJ, PFE, BMY, MRK, ABT

On Monday, current three major drug makers Eli Lilly & Co. (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), and Merck & Co., Inc. (NYSE:MRK) have decided to collaborate on a database that will assist speed up the investigational drug testing process. The firm will each contribute to a database, which will be made of doctors, hospitals and clinics keen to the testing of experimental medicines. Other pharmaceutical and biotech firm have also been requested to give to the database created by J&J’s Janssen Research & Development unit.

The head of Janssen’s clinical trial innovation and external alliances, Dr. Andreas Koester, stated that the present clinical trial environment is inefficient, costly and unsustainable. They are enthusiastic concerning working with other industry leaders to collectively apply their proficiency, capabilities and shared passion for advancing science and improving lives.

Moving readers toward the broader market, let’s consider percentage change in stocks prices of other stocks in the similar sector who contribute major role in the market that includes Pfizer Inc. (NYSE:PFE) up +1.34%, Bristol Myers Squibb Co. (NYSE:BMY) edged up 0.66%, Merck & Co., Inc. (NYSE:MRK) which also increased 0.46% and Abbott Laboratories (NYSE:ABT) closed up 0.54%.

Johnson & Johnson (NYSE:JNJ) stock’s trade at beginning with a price of $69.54 and in ongoing trading session climbed at a high of $69.77 other than after it traded advanced 0.53% to $69.57.

The stock is going forward its 52 week low with 17.14% and lagging behind from its 52 week high price with -4.35%. JNJ last month stock price volatility remained 1.23%.

JNJ stock institutional ownership remained 66.10% while insider ownership included 0.02%. In its share capital JNJ has 2.77 billion outstanding shares among them 2.76 billion shares have been floated in market exchange.

Company’s beta coefficient included 0.55. Beta factors measures the amount of market risk associated with market trade.


For consideration of being featured on WallstreetPR, contact:

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at

Published by Brendan Byrne

While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email ( or his Google+ page (